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Abstract
The purpose of this study was to develop nanoparticles made of cholesterol-conjugated
carboxymethyl curdlan (CCMC) entrapping epirubicin (EPB) and establish their in vitro
and in vivo potential. CCMC was synthesized and characterized by Fourier transform
infrared spectra (FT-IR) and proton nuclear magnetic resonance spectra (1H NMR). The
degrees of substitution (DS) of the cholesterol moiety were 2.3, 3.5 and 6.4,
respectively. EPB-loaded CCMC-3.5 nanoparticles were prepared by the remote loading
method. The physicochemical characteristics, drug loading efficiency and drug release
kinetics of EPB-loaded CCMC-3.5 nanoparticles were characterized. The in vitro
release profiles revealed that EPB release was sensitive to the pH as well as the drug
loading contents. The cellular cytotoxicity and cellular uptake were accessed by using
human cervical carcinoma (HeLa) cells. The EPB-loaded CCMC-3.5 nanoparticles
were found to be more cytotoxic and have a broader distribution within the cells than the
free EPB. The in vivo pharmacokinetics and biodistribution were investigated after
intravenous injection in rats. Promisingly, a 4.0-fold increase in the mean residence time
(MRT), a 4.31-fold increase in the half-life time and a 6.69-fold increase in the area
under the curve (AUC0→∞) of EPB were achieved for the EPB-loaded CCMC-3.5
self-assembled nanoparticles compared with the free EPB. The drug level was
significantly increased in liver at 24 and 72 h; however, it decreased in heart at 8 and
24 h compared with the free EPB. The in vivo anti-tumor study indicated that the
EPB-loaded CCMC-3.5 self-assembled nanoparticles showed greater anti-tumor
efficacy than the free EPB. Taken together, the novel CCMC self-assembled
nanoparticles might have potential application as anti-cancer drug carriers in a drug
delivery system due to good results in vitro and in vivo.
(Some figures in this article are in colour only in the electronic version)
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1. Introduction
In recent years, significant effort has been devoted to the
development of nanotechnology for drug delivery since it
offers a suitable means of delivering small molecular weight
drugs as well as macromolecules such as proteins, peptides
or genes by either localized or targeted delivery to the
tissue of interest [1]. Polymeric amphiphiles consisting of
hydrophilic and hydrophobic segments can form nanosized
self-assemblies with a hydrophobic core and a hydrophilic
shell due to the intra- and/or intermolecular interactions of
hydrophobic segments in aqueous media [2–4]. In recent
years, natural polysaccharides, such as chitosan, starch,
alginate, dextran and pullulan, have been widely studied
for medical uses owing to their highly stable, non-toxic,
biodegradable, biocompatible, low cost and abundance in
nature. Those polysaccharides have been hydrophobically
modified with long alkyl chains or cholesteryl groups to form
micelles or nanoparticles [5–9], which are used for trapping
hydrophobic substances or some bioactive macromolecules
such as polypeptides, proteins, vaccines and genes in
biomedical and pharmaceutical fields [10–12].
Curdlan, a microbial polysaccharide, is a naturally
occurring linear (triple helix) polysaccharide composed of
1,3-β-linked D-glucose units synthesized by Agrobacterium
spp. [13, 14]. Curdlan readily dissolves in dilute alkali
solutions; however, it is insoluble in water or acidic
solutions [13]. It has a potential inhibitory effect against AIDS
virus infection and blood anti-coagulant activity, as well as
low toxicity in vitro and in vivo [15, 16]. Carboxymethylated
curdlan (CMC), as a negatively charged curdlan derivative,
is known to have anti-tumor activity [17–19]. Although the
mechanism of its anti-tumor action is not clearly understood,
CMC may not act on tumor cells directly and it can be
used as an ideal biomedical material. Previously, we
synthesized deoxycholic acid modified-CMC and investigated
the behaviors of corresponding aggregates [20]. Moreover,
Na et al reported that a sulfonylurea modified-CMC derivative
was a useful drug carrier due to the immunological
enhancement activities of CMC, ligand–receptor-mediated
specific interactions and the controlled release of anti-tumor
drug [21]. Nevertheless, work on hydrophobically modified-
CMC self-assemblies has so far focused on the properties
in vitro.
Herein, based on our previous work, we synthesized
cholesterol-conjugated carboxymethyl curdlan (CCMC) and
prepared self-assembled nanoparticles by probe sonication
in aqueous media. Furthermore, we investigated the
behavior of epirubicin (EPB)-loaded CCMC nanoparticles
in vitro and in vivo. We chose cholesterol as the
hydrophobic segment in view of its biocompatibility and
well-known ability to drive the self-assembly of cholesteryl
containing amphiphilic polymers [22, 23]. In addition, the
hydrophobic core of these self-assembled nanoparticles formed
by hydrophobic interactions among the cholesterol moieties
was also considered to act as a reservoir of hydrophobic
substances. In this study, EPB was chosen as a model drug
to assess the potential of CCMC self-assembled nanoparticles
as carriers for anti-cancer drugs. EPB is an anti-neoplastic
agent derived from doxorubicin, which like doxorubicin exerts
its anti-tumor effects by interference with the synthesis and
function of DNA and is most active during the S phase of the
cell cycle. However, EPB therapy may cause some serious
side-effects such as allergic reactions, cardiotoxicity and
blood problems [24–26]. Therefore, CCMC self-assembled
nanoparticles were prepared and used as a carrier for EPB with
the hope of sustaining its release rate, prolonging its circulation
time, enhancing its therapeutic index and decreasing its toxic
effects.
2. Materials and methods
2.1. Materials
Curdlan (Mw 81 000) was purchased from Wako Co. (Japan).
EPB was purchased from Hisun Pharmaceutical Co. (Zhejiang,
China). Cholesterol and 1-ethyl-3-[3-(dimethylamino)propyl]
carbodiimide (EDC) were purchased from Sigma Co. (St Louis,
MO, USA). N-hydroxyl succinimide (NHS) and pyrene were
purchased from Aldrich Co. (Milwaukee, WI, USA). All
reagents for high performance liquid chromatography (HPLC)
analysis, including acetonitrile and methanol, were HPLC
grade. Other chemical reagents were of analytical grade and
obtained from commercial sources. All reagent water used
in the experiments was pretreated with the Milli-Q System
(Millipore Corporation, Bedford, MA, USA).
2.2. Synthesis of carboxymethyl curdlan (CMC)
Curdlan was carboxymethylated according to the method
described in the literature [20, 21, 27, 28]. Briefly, a suspension
of 3.0 g of curdlan in 80 ml of isopropyl alcohol was stirred at
room temperature for 30 min. Then, 8 ml of sodium hydroxide
solution (35%) was added dropwise to the suspension, and after
that vigorous stirring was continued at room temperature for
90 min. Next, 3.6 g monochloroacetic acid was added over
three separate intervals of 10 min each and the mixture was
stirred at 55 ◦C for 5 h. The suspended product was collected
by filtration and washed successively by methanol–acetic acid
(7:3, v/v), methanol–water (4:1, v/v), methanol and acetone,
respectively. The final precipitate was dissolved in water and
dialyzed against distilled water at room temperature for 3
days. The retentate was frozen and lyophilized to give the
product. The structure of CMC was identified by FT-IR and
1H NMR. The degree of substitution (DS) of the CMC sample
was 0.75 units of carboxymethyl group per glucose residue
determined by conductometric back titration [20, 27–29] and
by 1H NMR [21].
2.3. Synthesis of CCMC
Cholesterol was coupled to CMC by EDC/NHS-mediated ester
formation. The carboxyl groups of CMC powder (800 mg)
swollen in DMSO were activated by the addition of EDC
(670 mg) and NHS (200 mg), followed by magnetic stirring
at room temperature for 2 h. Then, different amounts
of cholesterol (0.20–0.50 mol cholesterol per mol of CMC
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carboxyl groups) dissolved in 10 ml THF were slowly added
into the DMSO solution containing CMC. The mixture was
reacted at 45 ◦C for 48 h. Then the reactant mixture was cooled
to room temperature and the suspended product was collected
by filtration and washed with water–THF (1:5, v/v) and THF,
respectively. Then, the product was dispersed in 20 ml distilled
water and exhaustively dialyzed against distilled water for 3
days using a dialysis tube (molecular weight cut-off 8–12 kDa),
and the distilled water was exchanged at intervals of 3–6 h.
Then, the sample was frozen and lyophilized to obtain the
white, cotton-wool-like product of CCMC conjugates.
The amount of cholesterol covalently bound to CMC
was determined by HPLC [7, 20, 30–32]. Briefly, 20 mg
of CCMC was accurately weighed into a sample preparation
tube, to which 6 ml of methanolic KOH solution was also
added. The tube was capped tightly, and vortex-mixed. Then
it was immersed in a 60 ◦C bath and kept for 2 h with intense
shocking at intervals of 30 min. Following heating, the tube
was cooled to room temperature, 10 ml of petroleum ether
was added, and the contents were vortexed vigorously for 1
min and then centrifuged. The organic layers were evaporated
under nitrogen and redissolved in 100 μl of methanol for
HPLC analysis. Individual calibration curves of recorded
peak area versus cholesterol concentration were made. HPLC
was performed by a LC-10ATV P pump, a manual injector
with a 20 μl fixed loop and a SPD-10AV P UV–vis detector
(Shimadzu, Kyoto, Japan) at 208 nm. A reverse phase column
(Scienhome C18, 4.6 mm × 150 mm, 5 μm) was used at 30 ◦C
and 20 μl samples were injected into this column for all the
analyses. The product was eluted with methanol at a flow rate
of 1.0 ml min−1. The DS of the cholesterol moiety, defined as
the number of cholesterol moieties per 100 glucose residues of
CMC, was calculated according to the following formula
DS = (c/MCholesterol)/[(m − c)/MCMC]
where c is the cholesterol content determined from the
corresponding calibration curve, m is the amount of CCMC
used in the experiment, MCholesterol is the molecular weight
of the cholesterol, and MCMC is the molecular weight of the
anhydroglucose units of CMC.
The IR spectrum of CCMC was obtained as KBr pellets
on a FT-IR spectrometer (Nicolet NEXUS 470-ESP, USA) at
room temperature. The 1H NMR spectrum of CCMC in the
solution of D2O/d6-DMSO (1/5, v/v) was acquired using a
600 MHz spectrometer (JEOL JNM-ECP 600, Japan).
2.4. Preparation of CCMC self-assembled nanoparticles
CCMC self-assembled nanoparticles were prepared by probe
sonication in distilled water. The starting procedure was as
follows: a certain amount of CCMC was suspended in distilled
water with gentle shaking at 37 ◦C for 12 h, followed by
sonication using a probe-type sonicator (Automatic Ultrasonic
Processor UH-500A, China) at 100 W for 2 min. The
sonication step was repeated three times until the desired size
had been reached. To protect the solution from build up of heat
during sonication, a pulse function was used (pulse on, 2.0 s;
pulse off, 2.0 s). The solution of self-assembled nanoparticles
was then filtrated through a 0.8 μm filter to remove dust and
impurities.
2.5. Characterization of CCMC self-assembled nanoparticles
To observe the morphology of CCMC self-assembled
nanoparticles, the sample solution (0.5 mg ml−1) was placed
on a carbon-coated copper grid, dried under vacuum at 30 ◦C
and measured by a transmission electron microscope (TEM;
Tecnai G2 20S-Twin, USA) at an accelerating voltage of 80 kV.
The size and size distribution of CCMC self-assembled
nanoparticles were measured by dynamic laser light scattering
(DLLS) with a digital autocorrelator (Brookhaven BI-90 Plus,
USA) at a scattering angle of 90◦, a wavelength of 633 nm
and a temperature of 25 ± 0.1 ◦C. The zeta potential of
CCMC self-assembled nanoparticles was measured using a
zeta potentiometer (Zetasizer 3000HS, Malvern Instruments
Ltd, Malvern UK) operated at 11.4 V cm−1, 13.0 mA
and 25 ◦C. The sample concentration was maintained at
0.5 mg ml−1 in distilled water.
2.6. Drug loading and in vitro release studies
EPB-loaded CCMC-3.5 self-assembled nanoparticles were
prepared by the remote loading method [33]. Briefly, 20 mg
of CCMC-3.5 was accurately weighed and suspended in 6 ml
of ammonium sulfate solution (0.15 M) with gentle shaking
at 37 ◦C for 24 h, followed by sonication using a probe-type
sonicator (Automatic Ultrasonic Processor UH-500A, China)
at 100 W for 2 min. Then it was dialyzed against NaCl solution
(0.9%, 100 ml) for 4 h using a dialysis tube (molecular weight
cut-off 8–12 kDa) with two exchanges of solution. Next,
4 ml of distilled water was added to the solution to give the
blank CCMC-3.5 self-assembled nanoparticles (2 mg ml−1).
Different amounts of epirubicin hydrochloride (EPB·HCl)
dissolved in distilled water were mixed with the blank CCMC-
3.5 self-assembled nanoparticles with gentle shaking in a dark
place for 24 h. An ultrafiltration method with a membrane
filter with a molecular weight cut-off 10 kDa (Amicon Ultra-4,
Millipore, USA) was used to remove the free EPB that was not
trapped inside the CCMC-3.5 self-assembled nanoparticles.
Ultrafiltration was repeated three times, and the EPB-loaded
CCMC-3.5 self-assembled nanoparticles were collected and
freeze-dried. The morphology of the EPB-loaded CCMC-3.5
self-assembled nanoparticles was observed by TEM. The size
and size distribution of EPB-loaded CCMC-3.5 self-assembled
nanoparticles were observed by DLLS. The loading capacity
and the encapsulation efficacy (loaded drug/initially added
drug) of EPB were determined by HPLC [34] as described
below.
The EPB release rate in vitro was measured by a dynamic
dialysis method in phosphate buffered saline (PBS, pH 7.4, 6.8
and 5.0). Briefly, 2 ml of the EPB-loaded CCMC-3.5 self-
assembled nanoparticle solution was placed into a dialysis tube
(molecular weight cut-off 8–12 kDa). Then, dialyzed against
20 ml of the above PBS solutions at 37 ± 0.2 ◦C in a dark
place with gentle shaking. At predefined time intervals, the
whole medium was removed and replaced by fresh PBS so as
to maintain a sink condition. The amount of EPB released was
determined by HPLC as described below.
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2.7. Cell culture
Human cervical carcinoma (HeLa) cells were acquired from
the Shanghai Institute of Cell Biology (Chinese Academy of
Sciences, Shanghai, China) and grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS) at 37 ◦C in a 5% CO2 humidified atmosphere.
2.8. In vitro cellular cytotoxicity assays
HeLa cells were seeded at a density of 5 × 103 cells ml−1 in a
96-well flat-bottomed plate and allowed to adhere overnight.
The medium was then replaced by the free EPB or EPB-
loaded CCMC-3.5 self-assembled nanoparticles dissolved and
diluted in DMEM at various drug concentrations of 0.01,
0.1, 0.5, 1, 5 and 10 μg ml−1. The blank CCMC-3.5 self-
assembled nanoparticles dissolved in DMEM were added as a
control. The nanoparticles were sterilized by added gentamicin
(50 μg ml−1). The solutions were removed after incubation
for 1 and 2 h. The cells were washed once with 100 μl of PBS
solution, incubated with 100 μl of fresh DMEM and cultured
at 37 ◦C in a 5% CO2 atmosphere for 48 h. Then, cell viability
was analyzed using MTS reagent (Promega) according to the
manufacturer’s directions [35]. Briefly, 20 μl of MTS reagent
was added and the cells were incubated for 2 h. Absorbance
was measured at 490 nm using a microplate reader (Thermo
Varioskan Flash 3001, USA). The results were expressed as a
percentage of the absorbance of the non-treated cells.
2.9. Cellular uptake experiment
The cells (2 × 104 cells ml−1) were cultured in T-25 flasks
at 37 ◦C for 24 h to allow cell attachment. Then, the
medium was replaced by the free EPB or EPB-loaded CCMC-
3.5 self-assembled nanoparticles dissolved in DMEM at drug
concentrations of 10 μg ml−1 for 2 h. After incubation, the
medium was removed and the treated cells were thoroughly
washed three times with PBS to remove the drug that was
not taken up by the cells, and then examined by a confocal
laser scanning microscope (FV1000, Olympus Co., Japan) at
an excitation wavelength of 488 nm. An emitting signal was
detected at 515 nm.
2.10. In vivo pharmacokinetics
All animal procedures were performed in accordance with
the guidelines issued by the committee on animal research
of Peking Union Medical College (PUMC), and approved
by the institutional ethics committee of PUMC. The in
vivo pharmacokinetics were measured with male Wistar rats
weighing 200–250 g and aged 4–6 weeks, which were supplied
by the Laboratory Animal Centre of the Institute of Radiation
Medicine, Chinese Academy of Medical Sciences (Tianjin,
China). The animals were held in air-conditioned facility and
provided with standard food and filtered water.
The free EPB or EPB-loaded CCMC-3.5 self-assembled
nanoparticles were diluted in normal saline containing 0.9%
w/v NaCl to obtain an estimated injection volume. Animals
were randomly assigned to two groups, each with six rats.
Each group received an intravenous injection of free EPB and
EPB-loaded CCMC-3.5 self-assembled nanoparticle solution
in saline via the tail vein at an equivalent dose of 10 mg kg −1,
respectively. All animals were observed for mortality, general
condition and potential clinical signs. The blood samples were
collected in heparinized tube from the retro-orbital plexus at
2, 5, 10, 15, 30 min, 1, 2, 4, 8, 12, 24, 36, 48, 96, 168 h
post-treatment. In each case plasma samples were harvested by
centrifugation (3000 rpm, 4 ◦C, 10 min) and stored at −40 ◦C
until analysis. Liquid–liquid extraction was performed prior to
the HPLC analysis. Briefly, the plasma (100 μl) was mixed
with 100 μl of 10 mM PBS (pH 7.8). The drug was extracted
with chloroform–methanol (4:1, v/v). The contents were
vortexed for 2 min and centrifuged at 8000 rpm for 10 min. The
upper aqueous layer was removed by aspiration and the organic
layer was transferred to a glass tube and evaporated under
nitrogen at 50 ◦C. The dried residue was redissolved in 100 μl
of methanol by vortexing and then measured by HPLC, the
apparatus consisting of a LC-10ATV P pump, a manual injector
with a 20 μl fixed loop and a SPD-10AV P UV–vis detector
(Shimadzu, Kyoto, Japan) at 232 nm. A reverse phase column
(Scienhome C18, 4.6 mm × 150 mm, 5 μm) was used at 35 ◦C
and 20 μl samples were injected into this column for all the
analyses. The mobile phase consisted of methanol, acetonitrile
and 0.2 M potassium dihydrogen phosphate (34:17:49, v/v/v)
and its flow rate was 1.0 ml min−1.
2.11. Tissue biodistribution study
To assess the effect of EPB-loaded CCMC-3.5 self-assembled
nanoparticles on tissue distribution of EPB, female Wistar rats,
180–220 g and 4–6 weeks old, were randomly assigned to
two groups with 12 rats in each. Each group received an
intravenous injection of free EPB and EPB-loaded CCMC-3.5
self-assembled nanoparticles via the tail vein at an equivalent
dose of 8 mg kg−1, respectively. Each group consisted of
four sets, each having three rats. Animals in each set were
exsanguinated through the femoral artery at 30 min, 8 h, 24 h
and 72 h, respectively, after the injection, and various tissues
such as heart, liver, spleen, lung and kidney were collected.
Tissue samples were blotted with paper towel, rinsed in saline,
blotted to remove excess fluid, weighed and homogenized
with PBS, pH 7.4. The mixture was extracted and evaporated
in the same way as the blood samples. Then, the dried
residue was redissolved in 200 μl of methanol by vortexing
and quantified spectrofluorometrically at λex 470 nm and λem
589 nm (Thermo Varioskan Flash 3001, USA) [36–38]. To
correct for background fluorescence, a standard curve was
obtained by spiking tissue extracts derived from rats that had
not received drug with EPB. The concentrations of EPB in
tissue were expressed as microequivalents per gram of tissue.
2.12. In vivo tumor growth inhibition study
The mouse hepatoma H22 cells (Institute of Radiation
Medicine, Chinese Academy of Medical Sciences, Tianjin,
China) were transferred into the abdominal cavity of 5–6-
week-old female Kunming mice. The ascites were taken
from the mice on a superclean bench and then diluted with
4
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Figure 1. Scheme for synthesis of CCMC.
physiological saline to 1 × 107 ml−1. A total 0.1 ml of
1 × 107 ml−1 H22 cells were inoculated by subcutaneous
injection in the right armpits of the mice to establish a solid
tumor model. Tumors were allowed to grow for approximately
1 week to a volume of 100–200 mm3. Then, tumor-bearing
mice were randomly divided into three groups of six each:
group I, with physiological saline only; group II, free EPB
at 8 mg kg−1; and group III, EPB-loaded CCMC-3.5 self-
assembled nanoparticles at 8 mg EPB kg−1. The treatments
were injected through the tail vein. After treatment, tumors
were measured every 2 days for 14 days, and tumor volumes
were calculated by the following formula: volume = a ×b2/2,
where a was the largest and b was the smallest diameter of the
tumor (mm).
2.13. Statistical analysis
Statistical analysis was conducted by using the Student’s t-test
with p < 0.05 as a significant difference. The experimental
results are given in the format of (mean ± SD) in the tables
and figures.
3. Results and discussion
3.1. Synthesis and characterization of CCMC
Curdlan was first carboxymethylated to yield the car-
boxymethylated derivative of CMC (figure 1) to improve its
solubility and bioactivity. Then, a cholesterol molecule was
covalently attached to CMC in the presence of EDC and
NHS, thus producing a novel kind of polymeric amphiphile
(figure 1).
Figure 2 shows the IR spectra of CMC and CCMC. The
peak assignment of CMC (figure 2(a)) is as follows (cm−1):
Figure 2. IR spectra of (a) CMC and (b) CCMC.
3500 (O–H stretch), 2886 (C–H stretch), 1735 (C=O stretch
of COO−), 1605 (COO−, as), 1442 (COO−, sy), 1087 (C–O
stretch). Compared with CMC, the absorption band at
1743 cm−1 was due to the formation of an ester group which
indicated that cholesterol was conjugated to CMC by ester
formation (figure 2(b)).
Figure 3 shows the 1H NMR spectra of CMC (D2O) and
CCMC (D2O/d6-DMSO, 1/5, v/v). Compared with CMC,
the signals of CCMC (figure 3(b)) at 0.99–3.15 ppm belong
to cholesterol moieties, which confirmed the introduction of
the cholesterol moieties into CMC. The DS of the cholesterol
moiety, defined as the number of cholesterol moieties per 100
glucose residues of CMC, was determined by HPLC. The
resulting DS of CCMC was 2.3, 3.5 and 6.4, respectively.
3.2. Preparation of CCMC self-assembled nanoparticles and
drug loading
The shapes of CCMC-3.5 self-assembled nanoparticles were
more regular than those of CCMC-2.3 and CCMC-6.4 (data
not shown), therefore CCMC-3.5 was chosen as a model
drug carrier. The CCMC-3.5 self-assembled nanoparticles
were simply prepared by sonication in aqueous media and
formed monodisperse nanoparticles with a relatively narrow
size distribution (figure 4(a)). The TEM image shows
that CCMC-3.5 self-assembled nanoparticles were spherical
(figure 4(b)), and their diameter appeared a little difference
from that determined by DLLS measurement. This was mainly
due to the process involved in the preparation of samples.
In the case of the TEM method, TEM images depicted the
size of the sample in the dried state, whereas the DLLS
method involved the measurement of size in the hydrated
state [26, 39]. As shown in table 1, the mean diameter
of CCMC self-assembled nanoparticles was in the range of
144–233 nm, which depends on the DS value. The mean
diameter of self-assembled nanoparticles decreased as the DS
increased, because increasing DS can increase the chances of
hydrophobic interactions between cholesterol groups bound to
5
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Figure 3. 1H NMR spectra of (a) CMC and (b) CCMC.
Figure 4. Size distribution (a) and TEM image (b) of CCMC-3.5 self-assembled nanoparticles.
Table 1. Characterization of CCMC in distilled water.




CCMC-2.3 2.3 233 0.185 −35.6
CCMC-3.5 3.5 208 0.141 −32.1
CCMC-6.4 6.4 144 0.228 −27.4
a Degree of substitution of cholesterol.
b Mean diameter and polydispersity determined by dynamic
laser light scattering (θ = 90◦).
c The zeta potential of CCMC in distilled water at
0.5 mg ml−1.
CMC, which results in the formation of stronger hydrophobic
cores [40]. The zeta potentials of CCMC self-assembled
nanoparticles were very negative in distilled water (table 1),
indicating that negatively charged carboxyl groups of CMC
covered the nanoparticles and that these nanoparticles were
electrostatically stabilized by the negatively charged CMC
shells, providing long term stability in the aqueous phase.
Epirubicin (EPB), an anti-cancer drug, is known as an
amphiphilic weak base (pKa = 7.7) due to its hydrophobic
anthracycline and hydrophilic sugar moiety. Therefore in
this study we used a remote loading method to physically
entrap it in the CCMC-3.5 self-assembled nanoparticles.
The characteristics of EPB-loaded CCMC-3.5 self-assembled
nanoparticles are listed in table 2. The drug loading contents
increased from 13.5% to 39.6% with the weight ratio of EPB to
CCMC-3.5 self-assembled nanoparticles increasing from 1/5
to 5/5, while the drug entrapment efficiency decreased from
78% to 65.6% at the same time. The mean diameter of EPB-
loaded CCMC-3.5 self-assembled nanoparticles increased
from 294.4 to 510.4 nm with increasing EPB content. It should
be mentioned that the products were not stable and preferred
to precipitate in an aqueous medium above the weight ratio
of drug to carrier (3/5). Thus, the optimal weight ratio (3/5),
based on the size, stability and the drug loading properties, was
selected to prepare EPB-loaded nanoparticles. TEM images
(figure 5) show that EPB-loaded CCMC-3.5 self-assembled
nanoparticles were almost spherical in shape and their size was
about 250 nm, which was smaller than the size determined by
DLLS (table 2) for the reason mentioned above.
3.3. In vitro drug release study
The drug release behavior was studied in vitro by a dialysis
method in PBS (pH 7.4, 6.8 and 5.0). As shown in figure 6(a),
EPB was released from the EPB-loaded CCMC-3.5 self-
assembled nanoparticles in a biphasic pattern, which was
6
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Table 2. Characteristics of EPB-loaded CCMC-3.5 self-assembled nanoparticles.
Drug/carrier a db (nm) Polydispersityb Loading content (%)c Loading efficiency (%)d
1/5 294.4 0.230 13.5 78.0
2/5 365.5 0.206 21.6 68.9
3/5 412.1 0.208 30.7 73.8
4/5 453.7 0.185 35.3 68.2
5/5 510.4 0.200 39.6 65.6
a EPB/CCMC self-assembled nanoparticles (mg mg−1).
b Mean diameter and polydispersity determined by dynamic laser light scattering (θ = 90◦).
c (Loading EPB/CCMC-3.5 self-assembled nanoparticles) × 100% (mean value) determined by
HPLC three times.
d (Loading EBP/feeding EPB) × 100% (mean value) determined by HPLC three times.
Figure 5. TEM image of EPB-loaded CCMC-3.5 self-assembled
nanoparticles.
characterized by an initial rapid release period in the first 10 h
followed by a slow uniform release. The burst release of EPB
may be due to the dissolution and diffusion of the drug that
was poorly entrapped in the polymer matrix, while the slower
and continuous release may be attributed to the diffusion of
the drugs inside the hydrophobic domain [41, 42]. It was
also observed that release of EPB from EPB-loaded CCMC-
3.5 self-assembled nanoparticles was sensitive to the pH of
the release medium as well as the drug loading content. As
shown in figure 6(a), EPB-loaded CCMC-3.5 self-assembled
nanoparticles with a drug loading content of 30.7% exhibited
an evident decrease in the release rate with increase in the
pH of the release medium, and similar release characteristics
were observed for the other drug loading contents (data not
shown). In PBS (pH 7.4), the EPB release from EPB-
loaded CCMC-3.5 self-assembled nanoparticles with a drug
loading content of 30.7% was very slow and the total amount
released was about 34.2% in 48 h. Therefore, CCMC-3.5
self-assembled nanoparticles had potential as sustained release
carriers of EPB. Figure 6(b) shows the effects of drug loading
content on the release rate, and reveals that the EPB release
rate decreased evidently with the increase in drug loading
content. This may be because the water-soluble EPB·HCl was
converted to hydrophobic EPB and partially precipitated inside
the nanoparticles during the remote drug loading process,
and the more hydrophobic EPB precipitated at the higher
weight ratio of drug/carrier, resulting in a higher drug loading
content. Due to the very low aqueous solubility of EPB, its
release rate (amount of released drug/amount of loaded drug)
from EPB-loaded CCMC-3.5 self-assembled nanoparticles in
a definite volume (20 ml) of release medium would decrease
with increasing drug loading content, e.g. about 61.6%, 42.4%
and 34.2% of the loaded drug was released in PBS (pH 7.4)
over 48 h corresponding to drug loading contents of 13.5%,
21.6% and 30.7%.
3.4. In vitro cellular cytotoxicity assays
The cytotoxic effects of free EPB or EPB-loaded CCMC-3.5
self-assembled nanoparticles on HeLa cells were evaluated
using the MTS assay (figure 7). CCMC-3.5 self-assembled
nanoparticles without EPB did not show any cytotoxic
effect on HeLa cells. Cell viability remained above 98%,
indicating that CCMC-3.5 self-assembled nanoparticles were
non-toxic and biocompatible. It can be seen from figure 7
that free EPB or EPB-loaded CCMC-3.5 self-assembled
nanoparticles at various drug concentrations decreased the
viability of HeLa cells in a dose-dependent and time-dependent
manner. EPB-loaded CCMC-3.5 self-assembled nanoparticles
exhibited slightly more cytotoxic to HeLa cells at low EPB
concentrations after 1 or 2 h incubation (<1 μg ml−1, p >
0.05) compared with free EPB. The inhibitory effects of EPB-
loaded CCMC-3.5 self-assembled nanoparticles increased
more rapidly with increase in drug concentration from 1 to
10 μg ml−1, and demonstrated a significant difference after
2 h incubation (p < 0.05) as compared with free EPB. In
addition, EPB-loaded CCMC-3.5 self-assembled nanoparticles
exhibited significantly higher cytotoxicity after 2 h incubation
(p < 0.05) in comparison with the only 1 h incubation above
the drug concentration of 1 μg ml−1. It is thus shown that
EPB-loaded CCMC-3.5 self-assembled nanoparticles greatly
enhance the therapeutic effects of EPB in vitro with increases
in drug concentration and incubation time.
3.5. Cellular uptake experiment
The cellular uptake of free EPB or EPB-loaded CCMC-
3.5 self-assembled nanoparticles was investigated by confocal
7
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Figure 6. EPB release from EPB-loaded CCMC-3.5 self-assembled nanoparticles with a drug loading content of 30.7% at 37 ◦C in PBS (pH
7.4, 6.8 and 5.0) (a), and with a drug loading content of 13.5%, 21.6% and 30.7% at 37 ◦C in PBS (pH 7.4) (b).
Figure 7. Cellular viability of HeLa cells after incubation with free
EPB and EPB-loaded CCMC-3.5 self-assembled nanoparticles for
1 h and 2 h, respectively. CCMC-3.5 self-assembled nanoparticles
without EPB were added as controls. Data are given as mean ± SD
(n = 4).
laser scanning microscopy (CLSM). Figure 8 shows CLSM
of HeLa cells after 2 h incubation with (a) free EPB and
(b) EPB-loaded CCMC-3.5 self-assembled nanoparticles at
the same drug concentrations of 10 μg ml−1. It can be
seen that the free EPB was mainly distributed within the
nucleus (figure 8(a)), while the EPB-loaded CCMC-3.5 self-
assembled nanoparticles can be observed around the nucleus
(figure 8(b)). This was because EPB molecules were
transported into the cells through a passive diffusion pathway
and mainly accumulated within the nucleus, with sparse
distribution in the cytoplasmic region near the cell membrane.
However, fluorescence was observed in the cytoplasm after
the EPB-loaded CCMC-3.5 self-assembled nanoparticles were
incubated with the cells for 2 h (figure 8(b)). It has been
reported that micelles or nanoparticles can be rapidly taken
up by cells via endocytosis [43]. They first reach mildly
acidic endosomes (pH 5.0–6.5) and then end up in lysosomes
Table 3. Pharmacokinetic parameters of free EPB versus
EPB-loaded CCMC-3.5 self-assembled nanoparticles after






a (mg l−1) 11.808 ± 3.089 17.200 ± 4.008
Tmax
b (h) 0.017 ± 0.000 0.038 ± 0.001
t1/2c (h) 6.480 ± 0.430 28.967 ± 3.216
MRT d (h) 6.225 ± 1.812 24.933 ± 5.091
AUC(0−t)e (h mg l−1) 56.821 ± 9.577 165.711 ± 19.734
AUC(0−∞)e (h mg l−1) 59.284 ± 10.008 396.712 ± 34.318
AUMC(0−t)f (h mg l−1) 342.130 ± 46.631 4836.390 ± 516.866
a Peak plasma concentration. b Time of peak plasma concentration.
c Half-life time. d Mean residence time.
e Area under the curve. f Area under the first moment curve.
(pH ∼ 4.5) where they face conditions of much lower pH
and possible enzymatic degradation [44]. Then, drug release
is triggered from the endocytosed nanoparticles and transit to
the cytoplasm.
3.6. In vivo pharmacokinetics
The plasma levels of EPB were determined following a
single injection of free EPB or EPB-loaded CCMC-3.5 self-
assembled nanoparticles (10.0 mg kg−1 EPB equiv) in male
Wistar rats. The resulting plasma levels are shown in figure 9
and the pharmokinetic parameters are shown in table 3. As
shown in figure 9, the free EPB disappeared rapidly from the
circulation due to its short half-life. The plasma concentration
of free drug was detected for up to 24 h and in very trace
quantities, and thereafter no drug was found. In contrast, the
EPB-loaded CCMC-3.5 self-assembled nanoparticles showed
a much longer circulation time and could be prolonged to
168 h. Furthermore, the drug concentration of the EPB-
loaded CCMC-3.5 self-assembled nanoparticles achieved a
much higher level in the plasma than the free EPB did during
the entire experiment.
From the table 3 it can be seen that the half-life of
the drug was 4.31 times longer for the EPB-loaded CCMC-
8
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Figure 8. Confocal laser scanning microscopy of HeLa cells after 2 h incubation with (a) free EPB and (b) EPB-loaded CCMC-3.5
self-assembled nanoparticles at the equivalent 10 μg ml−1 EPB concentration.
Figure 9. Pharmacokinetic profile of free EPB and EPB-loaded
CCMC-3.5 self-assembled nanoparticles after intravenous injection
in rats at a single equivalent dose of 10 mg kg−1 (mean ± SD and
n = 6).
3.5 self-assembled nanoparticles than that for the free EPB
(p < 0.05). The MRT (mean residence time) of the
formulation was found to be increased by about 4.01-fold in
comparison with the free drug (p < 0.05). The plasma
concentration versus time curve (figure 9) also revealed an
increased residence time of EPB-loaded CCMC-3.5 self-
assembled nanoparticles. This indicated the sustained release
profile of the drug from the EPB-loaded CCMC-3.5 self-
assembled nanoparticles compared with the free drug, which
was supported by its enhanced half-life, AUC0–168, AUC0–∞,
AUMC0–168 values. AUC(0→t), AUC(0→∞) and AUMC(0→t) of
EPB-loaded CCMC-3.5 self-assembled nanoparticles tend to
increase by almost by 2.92, 6.69 and 14.14 times, respectively
(p < 0.05). These results from the pharmacokinetic studies
reveal that the dug delivery system had a more prolonged
retention time in the plasma circulation, which is known as the
driving force for increased tumor targeting [45]; meanwhile,
it is acknowledged that highly porous tissues like tumor
tissue have augmented capillary permeability and might accrue
EPB-loaded CCMC-3.5 self-assembled nanoparticles via the
enhanced permeability and retention (EPR) effect. This will
supposed to show improved therapeutic efficacy.
3.7. Biodistribution
The biodistribution of free EPB and EPB-loaded CCMC-3.5
self-assembled nanoparticles in solid tissues such as heart,
liver, spleen, lung and kidney was investigated at four time
points: 0.5, 8, 24 and 72 h after injection. The results are
shown in figure 10, with graph (a) for free EPB and graph (b)
for EPB-loaded CCMC-3.5 self-assembled nanoparticles. As
shown in figure 10(a), free EPB was mainly distributed to the
heart and kidney at 0.5, 8, 24 and 72 h after injection, which
might cause acute toxicity and would be rapidly eliminated
9
Nanotechnology 21 (2010) 265601 L Li et al
Figure 10. The EPB levels (μg g−1) in heart, liver, spleen, lung and kidney after intravenous injection of 8 mg kg−1 drug equivalent of (a)
free EPB and (b) EPB-loaded CCMC-3.5 self-assembled nanoparticles (mean ± SD and n = 3).
from the circulation through glomerular filtration. Compared
with free EPB (figure 10(a)), the amount of drug in the
heart for EPB-loaded CCMC-3.5 self-assembled nanoparticles
dropped by 3.2- and 2.8-fold at 8 and 24 h, respectively
(p < 0.05) (figure 10(b)). Moreover, compared with free
EPB (figure 10(a)), the amount of drug in liver for EPB-
loaded CCMC-3.5 self-assembled nanoparticles increased by
2.4 and 3.1 times at 24 and 72 h, respectively (p < 0.05)
(figure 10(b)). The above data suggest that although the
kidney was the major clearance organ for the anti-cancer drugs
and the bioactives, the high molecular weight of CCMC-3.5
possibly helped to bypass glomerular filtration, the CCMC-3.5
being finally eliminated after metabolism in the liver. These
results indicate that CCMC-3.5 self-assembled nanoparticles
show a high targeting efficiency and a long retention time in
liver, which may imply reduced side-effects and thus increased
clinical significance.
3.8. In vivo tumor growth inhibition study
The in vivo anti-tumor efficacy of free EPB and EPB-loaded
CCMC-3.5 self-assembled nanoparticles was evaluated in H22
tumor-bearing mice at a dose of 8 mg kg−1 administrated
intravenously. As shown in figure 11, both free EPB and EPB-
loaded CCMC-3.5 self-assembled nanoparticles obviously
inhibited tumor growth compared with the control group on
day 14 after administration (p < 0.01). In particular, the
EPB-loaded CCMC-3.5 self-assembled nanoparticles showed
better anti-tumor activity as time went on compared with
free EPB, with a significant difference on day 14 after
administration (p < 0.01). This maybe attributed that the
EPB-loaded CCMC-3.5 self-assembled nanoparticles could
reach the tumor site through the EPR effect and maintain an
effective therapeutic concentration for a long period of time.
4. Conclusion
A novel kind of polymer amphiphile, cholesterol-conjugated
carboxymethyl curdlan, was synthesized. The chemical
structure of the conjugate was characterized by FT-IR and
1H NMR. EPB-loaded nanoparticles were prepared by the
Figure 11. In vivo anti-tumor effects of free EPB and EPB-loaded
CCMC-3.5 self-assembled nanoparticles on H22 tumor-bearing mice
after intravenous injection at a single equivalent dose of 8 mg kg−1.
Untreated controls received saline injection (mean ± SD and n = 6).
remote loading method with a high loading efficiency. The
EPB-loaded CCMC-3.5 nanoparticles showed much higher
cytotoxicity and broader distribution within the cells than
free EPB. However, in contrast to free EPB, no cytotoxicity
of the blank nanoparticles was observed. The in vivo
pharmacokinetics and biodistribution were investigated after
intravenous injection and the results showed that the EPB-
loaded CCMC-3.5 self-assembled nanoparticles resulted in
much higher AUC and much longer MRT and half-life
than free EPB. The EPB-loaded CCMC-3.5 self-assembled
nanoparticles significantly changed the tissue biodistribution
of the original drug. In particular, EPB-loaded CCMC-3.5
self-assembled nanoparticles significantly increased the uptake
of EPB in liver, but decreased the uptake in heart after
injection. The in vivo anti-tumor study revealed that the EPB-
loaded CCMC-3.5 self-assembled nanoparticles effectively
suppressed tumor growth compared with free EPB. Based
on these results, it could be concluded that CCMC-3.5
self-assembled nanoparticles can effectively solubilize EPB,
prolong its retention time in the plasma circulation, modify
10
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its tissue biodistribution and enhance the therapeutic efficacy
while reducing the systemic toxicity of EPB and thus may have
clinical significance.
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Marchand-Brynaert J, Feron O and Préat V 2009 J. Control.
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